Clover Health Investments financials
$4.33−3.56%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $743.2M | $749.2M | $487.7M | $496.6M | $477.6M | $462.3M | $337.0M | $331.0M | $356.3M | $346.9M | $312.4M | $306.0M |
| Gross profit | $153.0M | $159.5M | $74.2M | $73.2M | $99.6M | $108.9M | $93.9M | $81.2M | $356.3M | $81.8M | $62.6M | $70.2M |
| Gross margin | 20.6% | 21.3% | 15.2% | 14.7% | 20.9% | 23.6% | 27.9% | 24.5% | 100.0% | 23.6% | 20.0% | 23.0% |
| Operating income | $28.0M | $27.3M | -$49.3M | -$24.4M | -$10.6M | -$1.3M | -$21.4M | -$8.8M | $7.2M | -$22.7M | -$63.1M | -$33.6M |
| Net income | $28.0M | $27.3M | -$49.3M | -$24.4M | -$10.6M | -$1.3M | -$22.1M | -$9.2M | $7.4M | -$19.2M | -$70.5M | -$41.5M |
| Net margin | 3.8% | 3.6% | −10.1% | −4.9% | −2.2% | −0.3% | −6.6% | −2.8% | 2.1% | −5.5% | −22.6% | −13.6% |
| Diluted EPS | $0.05 | $0.05 | $-0.09 | $-0.05 | $-0.02 | $0.00 | $-0.04 | $-0.02 | $0.01 | $-0.04 | $-0.14 | $-0.09 |
| EBITDA | $28.1M | $27.4M | -$49.4M | -$25.3M | -$10.7M | -$1.2M | -$21.5M | -$11.1M | $8.7M | -$22.7M | -$45.2M | -$33.0M |
| Operating cash flow | $25.2M | $107.9M | -$68.2M | $12.1M | $5.4M | -$16.3M | -$85.8M | $50.0M | $44.8M | $25.9M | -$258.1M | -$18.8M |
| Free cash flow | $24.5M | $107.0M | -$68.7M | $11.4M | $4.8M | -$16.5M | -$86.1M | $49.6M | $44.4M | $25.5M | -$258.4M | -$19.0M |
| Diluted shares | 545.4M | 532.5M | 529.0M | 512.7M | 509.0M | 497.1M | 496.0M | 490.2M | 487.5M | 486.4M | 490.0M | 480.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $198.8M | $173.3M | $78.3M | $190.1M | $194.5M | $155.4M |
| Short-term investments | $44.3M | $30.3M | $42.0M | $12.8M | $27.0M | $4.7M |
| Total debt | $250.9M | $260.4M | $153.3M | $140.5M | $0.00 | $151.0M |
| Total assets | $720.3M | $697.7M | $541.0M | $559.7M | $580.7M | $583.7M |
| Total liabilities | $344.1M | $358.3M | $232.3M | $218.7M | $239.6M | $247.6M |
| Shareholders' equity | $376.3M | $339.4M | $308.7M | $340.9M | $341.1M | $336.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology